Moscow [Russia], September 15 : The Russian Direct Investment Fund (RDIF) on Wednesday announced the real-world data of Belarus’s Health Ministry on the Russian Sputnik V coronavirus vaccine confirming its high efficacy during the vaccination campaign in the country.
An official release stated that the Russian vaccine has demonstrated 97.2 per cent efficacy against coronavirus in Belarus. The efficacy of Sputnik V was measured based on data from more than 860,000 people vaccinated between January and July 2021. The data from the Ministry of Health also confirms high safety of Sputnik V, “No severe adverse events associated with vaccination. No deaths related to the vaccination. Belarus was the first foreign country to register Sputnik V and use it for vaccination of the population.”
RDIF and partners have facilitated the technology transfer to localise the production of Sputnik V by Belarus’s Belmedpreparaty company, which is successfully manufacturing Sputnik V. In April 2021 the vaccine produced in Belarus was authorised by the Ministry of Health.
In April 2021 the single-dose Sputnik Light vaccine (the first component of Sputnik V based on human adenovirus serotype 26) was also registered in Belarus.
Must Read
- Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy…
- PM Modi stresses on 'test, track and treat' with same…
- Sputnik Light Covid vaccine gets permission for Phase 3…
- Poland might close borders with Belarus over migrants
- Belarus sentence mass protest leader Maria Kolesnikova to 11…
- EU top diplomats to discuss situation in Belarus next Monday
- Some 1,000 refugees in Belarus ready to return to Iraq
- Hope: Negotiations between Russia and Ukraine begin in…
- Russia made proposals to Ukraine in form of legal documents…
- Australia reports record-high COVID-19 cases amid battle…